Search Immortality Topics:

Page 10«..9101112..2030..»


Category Archives: Biotechnology

Vir Biotechnology (VIR) Stock: Why It Increased Over 5% Today – Pulse 2.0

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 5% during intraday trading today. Investors are responding positively to Vir Biotechnology announcing new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. And the data was presented in one oral and two poster presentations at the International Liver Congress (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).

In summary, the data presented at ILC demonstrated that a six-dose regimen of VIR-2218 provided greater and more durable reductions in hepatitis B surface antigen (HBsAg) than a two-dose regimen, with all participants achieving a >1 log10 IU/mL reduction during the trial. Phase 1 results evaluating VIR-3434 showed that a single dose (6 mg, 18 mg, 75 mg or 300 mg) resulted in a rapid reduction of HBsAg, with the largest and most durable response noted with the 300 mg dose. Finally, preclinical in vivo data demonstrated that the combination of both investigational compounds resulted in greater HBsAg reductions than either compound alone.

As part of its ongoing efforts to advance its broad HBV portfolio, Vir is expecting to dose the first patient in Part B of the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 in combination with VIR-3434 for 24 and 48 weeks, and in combination with interferon, by the end of June. And previously reported results from Part A demonstrated that VIR-3434 combined with VIR-2218 provided an additional 2 log decline in HBsAg loss over the 3 log decrease with VIR-2218 alone. No drug-related safety signals were observed. The additional data from Part A are expected later this year. However, with clinical trial sites in Ukraine and Moldova, the Company is continuing to monitor the war in Ukraine for any potential impact on timing.

The additional milestones expected in the second half of 2022 include:

Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-.

Initial data from the Phase 2 trial led by Brii Biosciences evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection.

The initiation of a Phase 2 platform trial of VIR-2218 in combination with VIR-3434 in viremic patients (THRIVE/STRIVE sub-protocols), with initial data expected in the second half of 2023.

The initiation of a Phase 2 trial of VIR-2218 in combination with VIR-3434 for the treatment of chronic hepatitis D virus (HDV) infection, with initial data expected in 2023.

The company also expects to report initial data from the Phase 2 trial evaluating various combinations of VIR-2218, selgantolimod (GS-9688), Gilead Sciences investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor, as a potential cure regimen for chronic HBV infection in the first half of 2023.

KEY QUOTE:

The data presented at the International Liver Congress 2022 continue to indicate that our therapeutic strategy of combining an antiviral with an immunomodulator to restore immunologic control in patients with chronic HBV is additive and offers the potential for a functional cure. As we continue to evaluate VIR-2218 and VIR-3434, we are encouraged by the potential of these two investigational medicines alone and in combination. These data, alongside the anticipated initiation of Part B of the MARCH trial by the end of June, are important milestones in our broad HBV portfolio for which we expect multiple data readouts throughout 2022 and 2023.

Carey Hwang, M.D., Ph.D., Virs senior vice president, clinical research, head of chronic infection

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

See more here:
Vir Biotechnology (VIR) Stock: Why It Increased Over 5% Today - Pulse 2.0

Posted in Biotechnology | Comments Off on Vir Biotechnology (VIR) Stock: Why It Increased Over 5% Today – Pulse 2.0

The Termeer Foundation Selects Inaugural Termeer Scholars: CRISPR Pioneers and Biotechnology Innovators Omar Abudayyeh and Jonathan Gootenberg of MIT…

BOSTON--(BUSINESS WIRE)--The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the inaugural recipients of the 2022 Termeer Scholars Awards. These prestigious new awards support emerging biomedical researchers developing scientific advances like new medicines and diagnostics that represent the future of the biotechnology industry and the potential to positively impact patients lives.

This years co-recipients of the Termeer Scholars Award are Omar Abudayyeh and Jonathan Gootenberg, McGovern Institute Fellows at the Massachusetts Institute of Technology (MIT) whose lab is leveraging natural biological systems, including CRISPR biology, to develop a suite of tools for next-generation cellular engineering. These tools have been adopted by researchers over the world and formed the basis for four companies that Omar and Jonathan have co-founded. They will receive a $50,000 grant to support professional development, knowledge advancement and/or stakeholder engagement and will become part of The Termeer Foundations signature Network of Termeer Fellows (first-time CEOs and entrepreneurs) and Mentors (experienced industry leaders).

The Termeer Foundation is working to improve the long odds of biotechnology by identifying and supporting future biotech leaders; if we help them succeed as leaders, we can help their innovations reach patients. While our Termeer Fellows program has supported first time CEOs and entrepreneurs for the past five years, our new Termeer Scholars program will provide much needed support to the researchers whose innovative ideas represent the future of the biotechnology industry - researchers like Omar and Jonathan, said Alan Walts, Co-Founder and Member of the Board of Directors for The Termeer Foundation.

The Abudayyeh-Gootenberg lab at MIT is developing a suite of new tools to enable next-generation cellular engineering, with uses in basic research, therapeutics and diagnostics. Building off the revolutionary biology of natural biological systems, including mobile genetic elements and CRISPR systems, the team develops new approaches for understanding and manipulating genomes, transcriptomes and cellular fate. The technologies have broad applications, including in oncology, aging and genetic disease.

Omar Abudayyeh is a McGovern Institute Fellow at MIT. He was part of the Harvard-MIT Health Sciences and Technology program as an MD/PhD student and completed his doctoral work in Feng Zhangs lab at the Broad Institute, where his research centered on novel CRISPR enzymes for applications in genome editing, therapeutics, and diagnostics. Dr. Abudayyeh was recognized as a Technology Review TR35 Innovator, Endpoints 20 under 40 awardee, 2018 Forbes 30 under 30 in Science and Health Care, and Business Insider 30 under 30.

Jonathan Gootenberg is a McGovern Institute Fellow at MIT and received his PhD in Systems Biology from Harvard University, during which he conducted research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute. During his PhD, Gootenberg focused on the development of molecular technologies for treating and sensing disease states, crossing disciplines by utilizing novel computational techniques, microbiology, biochemistry, and molecular biology to uncover new CRISPR tools, including Cas12 and Cas13. He and his co-authors developed Cas13 into a toolbox with uses in fundamental research, therapeutics, and diagnostics. He has received multiple awards, including the Technology Review TR35, Forbes 30 Under 30, Endpoints 20 Under 40, and Business Insider 30 and Under.

"The Termeer Foundation is committed to championing emerging biotechnology leaders and finding people who want to solve the biggest problems in human health, said Belinda Termeer, President of The Termeer Foundation. "By supporting researchers like Omar and Jonathan, we plant the seeds for future success in individuals who are preparing to make significant contributions in academia and industry.

Abudayyeh and Gootenberg were honored at the Termeer Foundations annual dinner in Boston on June 16, 2022. The event also recognized the 2022 class of Termeer Fellows.

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundations network of emerging and established healthcare innovators cultivates tomorrows leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at http://www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

Here is the original post:
The Termeer Foundation Selects Inaugural Termeer Scholars: CRISPR Pioneers and Biotechnology Innovators Omar Abudayyeh and Jonathan Gootenberg of MIT...

Posted in Biotechnology | Comments Off on The Termeer Foundation Selects Inaugural Termeer Scholars: CRISPR Pioneers and Biotechnology Innovators Omar Abudayyeh and Jonathan Gootenberg of MIT…

Biotechnology Algae Cultivation Process (Micro Algae) Market Size And Forecast to 2028 |Cellana, Ecoduna, Algenol Biofuels, Solix Biofuels, Sapphire…

The Biotechnology Algae Cultivation Process (Micro Algae) Market researchexamines market estimates and predictions innicedetail. Itadditionallyaidswithin theexecutionof thosefindings by demonstrating tangiblebenefitsto business stakeholders andbusinessleaders.eachcompanyshouldanticipatehowevertheir productare going to beutilized inthe longer term. Giventhislevel of uncertainty caused by the COVID-19state of affairs, thisanalysisisessentialforhigherunderstanding previous disruptions and increasing readiness forsuccessivesteps in decision-making.the foremostrecent studymakes an attempttoaltertheadvancedmarketplace forcompanyexecutives by providing strategic insights and exhibiting resiliency insuddenconditions. The insightswillassist all potential readers indistinguishingnecessarybusinessbottlenecks.

The primary objective of the report is to educate business owners and assist them in making an astute investment in the market. The study highlights regional and sub-regional insights with corresponding factual and statistical analysis. The report includes first-hand, the latest data, which is obtained from the company website, annual reports, industry-recommended journals, and paid resources. The Biotechnology Algae Cultivation Process (Micro Algae) report will facilitate business owners to comprehend the current trend of the market and make profitable decisions.

Market Leaders Profiled:

Report Analysis & Segments:

The Biotechnology Algae Cultivation Process (Micro Algae) is segmented as per the type of product, application, and geography. All of the segments of the Biotechnology Algae Cultivation Process (Micro Algae) are carefully analyzed based on their market share, CAGR, value and volume growth, and other important factors. We have also provided Porters Five Forces and PESTLE analysis for a deeper study of the Biotechnology Algae Cultivation Process (Micro Algae).The report also constitutes recent development undertaken by key players in the market which includes new product launches, partnerships, mergers, acquisitions, and other latest developments.

Based on Product Type Biotechnology Algae Cultivation Process (Micro Algae) is segmented into

Based on the Application Biotechnology Algae Cultivation Process (Micro Algae) is segmented into

The report provides insights on the following pointers:

1 Market Penetration: Comprehensive information on the product portfolios of the top players in the Biotechnology Algae Cultivation Process (Micro Algae).

2 Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

3 Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market.

4 Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

5 Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Biotechnology Algae Cultivation Process (Micro Algae).

Schedule a Consultation Call With Our Analysts / Industry Experts to Find a Solution For Your Business @ https://www.marketresearchintellect.com/ask-for-discount/?rid=375531

Various Analyses Covered:

Regional assessment of the Biotechnology Algae Cultivation Process (Micro Algae) has been carried out over six key regions which include North America, Asia-pacific, Europe, Latin America, Middle East, and Africa. Moreover, the report also delivers deep insights on the ongoing research & development activities, revenue, innovative services, the actual status of demand and supply, and pricing strategy. In addition to this, this report also delivers details on consumption figures, export/import supply, and gross margin by region. In short, this report provides a valuable source of guidance and clear direction for the marketer and the part interested in the market.

North America(United States, Canada)Asia Pacific(China, Japan, India, South Korea, Australia, Indonesia, Others)Europe(Germany, France, United Kingdom, Italy, Spain, Russia, Others)Latin America(Brazil, Mexico, Others) The Middle East and Africa

Frequently Asked Questions:

About Us:Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:Mr. Steven FernandesMarket Research IntellectNew Jersey (USA)Tel: +1-650-781-4080

Email:sales@marketresearchintellect.com

Website: https://www.marketresearchintellect.com/

Link:
Biotechnology Algae Cultivation Process (Micro Algae) Market Size And Forecast to 2028 |Cellana, Ecoduna, Algenol Biofuels, Solix Biofuels, Sapphire...

Posted in Biotechnology | Comments Off on Biotechnology Algae Cultivation Process (Micro Algae) Market Size And Forecast to 2028 |Cellana, Ecoduna, Algenol Biofuels, Solix Biofuels, Sapphire…

BRIM Biotechnology enters OTC trading in Taiwan – Bio-IT World

Taipei, Taiwan, 23rdJune 2022 /SciadNewswire/BRIM Biotechnology, Inc.(BRIM, TWSE 6995) enters OTC trading in Taiwan on 23rdJune 2022, CST. The news was announced at the companys first earnings call on 22ndJune 2022.

Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM applies world-leading expertise in translational science to accelerate the development of early research technology platforms to clinical drug candidates. BRIM is led by Chairwoman and CEO Dr. Haishan Jang, and the companys current paid-in capital is approximately 23 million USD.

BRIM has several novel drug products in its pipeline, all underpinned by the companys proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform.

BRIMs lead candidate BRM421 has the potential to be a first-in-class peptide treatment for Dry Eye Syndrome (DES). Phase II/III clinical trials completed in the U.S. demonstrate that the drug has the potential to speed up the repair of corneal damage through stimulation of corneal stem cell proliferation and differentiation, as well as to treat disease symptoms. Data demonstrate that BRM421 is safe and well-tolerated with a unique early onset curative effect1.

In only seven years, BRIM has progressed BRM421 from pre-clinical to late-stage clinical trials and has successfully licensed the commercial rights in greater China (China, Hong Kong, and Macau) to Grand Pharma (China) Co., Ltd (HK00512). The rapid development and significant licensing deals reflect the unique advantage of the PDSP technology platform and BRIMs expertise.

Dr. Jang commented, Our goal is restoration and repair of the damage caused by DES. The PDSP technology platform underpinning BRM421 and other assets in our pipeline could revolutionize the ophthalmology and degenerative joint disease fields. If successful, BRM421 could treat millions of people around the world living with DES and provide an excellent example of a first-in-class new drug developed in Asia. OTC trading brings us one step closer to achieving our vision to bring sustainable and affordable healthcare innovation to the world.

DES is a common yet complex chronic disease. According to Global Data (2020)2, the DES market size in 2018 was approximately 3.9 billion USD across nine markets (US, France, Germany, Italy, Spain, UK, Japan, China, and India). This market is expected to grow in scale and size due to heavy screen-time usage, greater use of contact lenses and increasing numbers of eye surgeries3. Global Data predicts that the DES market size will reach approximately 11 billion USD in 20282. Research also suggests that COVID-19 increases the risk of developing DES4.

Currently, treatment options for DES are very limited and most treat the symptoms rather than the disease. Existing treatments include anti-inflammatories or artificial tears and lubricants, none of which repair the damage caused by DES.

Peptides shorter than 40 amino acids, such as BRM421, are categorized as small molecules, meaning they follow the New Drug Application (NDA) regulatory pathway rather than the Biologics License Application (BLA) pathway. This significantly reduces development time and costs, making novel peptides an attractive new treatment option for many pharmaceutical companies.

Beyond BRM421, BRIMs PDSP technology platform can be applied across multiple therapy areas and indications. Early research indicates that the PDSP technology platform demonstrates efficacy in corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration. BRIM has a rapidly expanding pipeline which includes treatments for severe corneal damage (BRM423), and osteoarthritis (BRM521).

With this next step of OTC trading, we are excited to progress development at an accelerated pace and will continue our journey in ophthalmology to bring the first regenerative peptide therapy for DES to the market in the near future, as well as apply our learnings to a wide range of other diseases with significantly unmet needs, said Dr. Jang.

BRIM Biotechnology, Inc.Shih-Ya ChangT: 886 2 2659 8586 #111E:info@brimbiotech.com

Sciad CommunicationsMaria Patey / Sophie ProtheroeT: 020 3405 7892E:BrimBiotech@sciad.com

About BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. is a clinical-stage company developing novel regenerative therapies in ophthalmology and degenerative joint diseases. Established in July 2013 to accelerate the development and transformation of early research technology platforms to clinical drug candidates, BRIM applies world-leading expertise in translational science to develop new treatments that help combat and cure disease. The companys virtual business model, combined with its proprietary PDSP technology platform, bridges the gap between research and clinical development faster, de-risks the process, and accelerates the progression of early-stage candidates in indications with high unmet medical needs.

For more information, please visitwww.brimbiotech.com.

More here:
BRIM Biotechnology enters OTC trading in Taiwan - Bio-IT World

Posted in Biotechnology | Comments Off on BRIM Biotechnology enters OTC trading in Taiwan – Bio-IT World

Northern Trust Appointed to Provide Asset Servicing Solutions to International Biotechnology Trust – Business Wire

LONDON--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) has been appointed to provide global custody, fund accounting, depositary services and its outsourced trading service Integrated Trading Solutions to International Biotechnology Trust and its investment manager SV Health Managers.

Founded in 1994, International Biotechnology Trust is a United Kingdom (UK) investment trust, that, as at end of May 2022, had a market capitalisation of over 255 million. Publicly-traded on the London Stock Exchange, its objective is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies with the potential for high growth through the development and/or commercialisation of a product, device or enabling technology.

Laurence Everitt, head of Global Fund Services, UK at Northern Trust said: We are delighted to partner with International Biotechnology Trust and SV Health Managers in delivering the administration, execution and technology capabilities they and their investors require. Our Whole Office approach to working with investment managers allows us to deliver these solutions via a single platform and integrated service model reducing business complexity for clients while helping us meet their evolving requirements.

Northern Trusts Global Fund Services business provides services including fund administration, global custody, investment operations outsourcing and data solutions to global investment managers supporting a range of complex investment strategies across the full spectrum of asset classes.

Integrated Trading Solutions is part of Northern Trust Capital Markets, which is comprised of a number of Northern Trust entities that provide trading and execution services on behalf of institutional clients, including institutional brokerage, foreign exchange, securities lending and transition management.

About Northern Trust

Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 22 U.S. states and Washington, D.C., and across 23 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2022, Northern Trust had assets under custody/administration of US$15.5 trillion, and assets under management of US$1.5 trillion. For more than 130 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Please visit our website or follow us on Twitter.

Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Please read our global and regulatory information.

http://www.northerntrust.com

Go here to read the rest:
Northern Trust Appointed to Provide Asset Servicing Solutions to International Biotechnology Trust - Business Wire

Posted in Biotechnology | Comments Off on Northern Trust Appointed to Provide Asset Servicing Solutions to International Biotechnology Trust – Business Wire

Biotechnology Act to Crash Cost of Vaccines, Drugs Import, Drive Research THISDAYLIVE – THISDAY Newspapers

With the passage of the Biotechnology Act by the National Assembly and its assent by President Muhammadu Buhari, the Chief Executive Officer of Biotechnology Development Agency, Prof. Abdullahi Mustapha, opined that it will crash the high cost of vaccine and medicine importation into the country.Chiamaka Ozulumba reports

The Chief Executive Officer (CEO), National Biotechnology Development Agency (NABDA), Prof. Abdullahi Mustapha, has said the passage of the Biotechnology Act by members of the National Assembly and assented by President Muhammadu Buhari will crash the high cost of vaccine and medicine importation into the country.

The good thing about the passage of the Act, he acknowledged, is that the era of importation of substandard drugs is surely coming to an end because local production of medicinal and vaccines products will lead to quality enhancement.On the free fall of the naira, the NABDA boss, expressed optimism that when pharmaceutical companies start local manufacturing of drugs, the strength of the naira will regain its value.

Mustapha, expressed excitement that the agency is hitting the ground running on deployment of research activities, adding that the Act will fuel research as it indexes Nigerias readiness to harness cutting-edge technologies for sustainable development, particularly, those that guarantee better life for all Nigerians.

On food security, Mustapha, said the law which confers legal authority on the agency to conduct research in biotechnology will drive Nigerias food security, industry, job creation and environment for national development.

He commended the lawmakers for the passage of the Act in April even as he added that they have demonstrated sound understanding of the dynamics of development in a globalised knowledge economy, specifically using biotechnology.

Briefing the media on the significance of the law at NABDA Headquarters in Abuja over the weekend, Mustapha, said the agency now has a legal framework that guides and guards its researches, aimed at boosting agricultural produce, promoting environmental sustainability, development of vaccines and drugs.

According to him, no nation can insulate science from its development agenda and thrive. This is particularly true, if the nation seeks to replicate the amazing development miracle of the Asian Tigers, he added.

As a developing nation with a low-income economy, he said Nigeria must conduct research to accelerate national development, lower Nigerias debt burden, and extricate it from the poverty trap.

Biotechnology, the NABDA boss added, is an accelerator of inclusive national growth that provides a knowledge-based approach to solving public challenges, and ensuring future sustainability, as witnessed in the height of COVID-19 Pandemic, where biotechnology provided a quick and safe solution.

With this development, we are optimistic that the agency will be able to consolidate Nigerias leadership in Africas biotechnology space, and launch the nation into the stratosphere of global economic players.

The Act makes NABDA; a body corporate with perpetual succession and a common seal. It is heartening to note that this development has moved NABDA from the realm of a promotional agency to that of a research institution.

It has strategically poised NABDA to pursue its mandate of driving national development by ethically harnessing applications of biotechnology. Some of these applications which are vital to Nigerias development are:

First, green biotechnology, which encompasses the agricultural field; second, red biotechnology, which relates to the medical field; third, blue biotechnology, which consists of the aquatic field; fourth, white biotechnology, which is about the industrial domain.

In addition, the Act will enable the agency draw up programmes and policies for biotechnology utilisation in Nigeria as well as create an avenue to publish and disseminate research findings and recommendations of the agency on biotechnology.

The passage of the Act will be a catalyst for the stimulation of rapid commercialisation of Biotechnology Research and Development products.

It will afford the agency a platform to collaborate with International Research Centres, NGOs, national and international biotechnology agencies and institutions, and ensure a sustainable mechanism for adequate funding of biotechnology activities through national and international funding agencies.

On Public Private Partnership (PPP), he said the Act recognises the imperative of the collaboration for groundswell private-sector participation in biotechnology enterprises, stressing that it stipulates that NABDA should coordinate and conduct strong advocacy programmes, seminars, conferences and workshops to foster multi-stakeholders cooperation for inclusive national development.

I am optimistic that private sector participation in biotechnology will extend the frontiers of economic development, and thereby, abate Nigerias over reliance on petrodollar. he said.

Mustapha, said private sector participation is needed for the mass production, commercialisation, and supply to end-users of the Bio-digesters invented by the agency, adding: As you are aware, the biodigesters which were locally fabricated with locally sourced material, would foster energy generation and efficiency.

He said: The research efforts of the agency are contributing enormously to abate exchange rate volatilities in Nigeria. A good example of this is cotton lint, a raw material for textile manufacturing. It was key on Nigerias import list, he said.

However, due to NABDAs collaboration with the Institute of Agricultural Research (IAR), Zaria, and Bayer and Mahyco Agricultural Nigeria Ltd, for the development, commercialization and deployment of new varieties of transgenic hybrid cotton, import of cotton lint is declining.

He said: Very soon, we shall attain self-sufficiency in the production of cotton. The point to underscore is, this Act by extension, would catalyze a resurgence of Nigerias Textile Industry.

Recall that the Textile Industry in Nigeria was a major employer of labour and revenue-earner in the 70s.

Furthermore, the agency, recently, formalized partnership with the Government of Cuba. The main objective of the partnership is to promote joint research in Tissue Culture, Drug and Vaccine manufacturing.

Speaking further, he said: Because of my background as an academic and actor in policy making space, it gives me a certain sense of elation to inform you that the Act, also, underlines the important nexus between innovative practice of biotechnology and research.

The Act encourages bridging the gap between laboratories and markets. It stipulates the formation of collaborative enterprises among research institutions and commercial sector.

This is why since my assumption of office as the Director General of NABDA, the commercialisation of research findings has been my clarion call.

QuoteWith this development, we are optimistic that the agency will be able to consolidate Nigerias leadership in Africas biotechnology space, and launch the nation into the stratosphere of global economic players

More here:
Biotechnology Act to Crash Cost of Vaccines, Drugs Import, Drive Research THISDAYLIVE - THISDAY Newspapers

Posted in Biotechnology | Comments Off on Biotechnology Act to Crash Cost of Vaccines, Drugs Import, Drive Research THISDAYLIVE – THISDAY Newspapers